The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Calcitonin controls bone formation by inhibiting the release of sphingosine 1-phosphate from osteoclasts
Open accessAbstract
The hormone calcitonin (CT) is primarily known for its pharmacologic action as an inhibitor of bone resorption, yet CT-deficient mice display increased bone formation. These findings raised the question about the underlying cellular and molecular mechanism of CT action. Here we show that either ubiquitous or osteoclast-specific inactivation of the murine CT receptor (CTR) causes increased bone formation. CT negatively regulates the osteoclast expression of Spns2 gene, which encodes a transporter for the signalling lipid sphingosine 1-phosphate (S1P). CTR-deficient mice show increased S1P levels, and their skeletal phenotype is normalized by deletion of the S1P receptor S1P 3 . Finally, pharmacologic treatment with the nonselective S1P receptor agonist FTY720 causes increased bone formation in wild-type, but not in S1P 3 -deficient mice. This study redefines the role of CT in skeletal biology, confirms that S1P acts as an osteoanabolic molecule in vivo and provides evidence for a pharmacologically exploitable crosstalk between osteoclasts and osteoblasts.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Calcr ϩ/Ϫ (hemizygous): high bone mass, increased bone formation.”
From The Activity of Peptides of the Calcitonin Family in Bone (2019) · cites this paper as [119]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Recently, procalcitonin has been shown to inhibit osteoclast differentiation in bone marrow cultures, and interestingly, this activity was not mediated by the calcitonin receptor (CTR) (119).”
From The Activity of Peptides of the Calcitonin Family in Bone (2019) · cites this paper as [119]
The cited source says what the claim attributes to it.
In the citing paper
“Similar to the previous models of CTR deficiency, the Calcr KO mice had high bone mass because of increased bone formation, a phenotype that was then reproduced in mice that had the gene deletion restricted to the osteoclast lineage.”
From The Activity of Peptides of the Calcitonin Family in Bone (2019) · cites this paper as [119]
The cited source says what the claim attributes to it.
In the citing paper
“The study found that the loss of CTR in osteoclasts increased the levels of sphingolipid transporter 2 (SPNS2), an exporter protein required for the secretion of sphingosine-1-phosphate (S1P), which is a potent inducer of bone formation.”
From The Activity of Peptides of the Calcitonin Family in Bone (2019) · cites this paper as [119]
The cited source says what the claim attributes to it.
In the citing paper
“Therefore, according to this study, calcitonin binding to CTR on osteoclasts inhibits the expression of SPNS2, causing a drop in S1P secretion and inhibition of osteoblast activity caused by the reduced levels of S1P (119).”
From The Activity of Peptides of the Calcitonin Family in Bone (2019) · cites this paper as [119]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Parfitt, A. M., Drezner, M. K., Glorieux, F. H., Kanis, J. A., Malluche, H., Meunier, P. J., Ott, S. M., & Recker, R. R. (1987) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650020617 · Cited by 5,016
How many drug targets are there?
Overington, J. P., Al-Lazikani, B., & Hopkins, A. L. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2199 · Cited by 3,505
Bone Histomorphometry : Standardization of Nomenclature, Symbols, and Units
PARFITT, A. M., Drezner, M. K., Glorieux, F. H., Kanis, J. А., Malluche, H. H., Meunier, P. J., Ott, S. M., & Recker, R. R. (1987) · Journal of Bone and Mineral Research · Cited by 3,258
Osteoporosis: now and the future
Rachner, T. D., Khosla, S., & Hofbauer, L. C. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62349-5 · Cited by 2,696
Self-citationConditional gene targeting in macrophages and granulocytes using LysMcre mice
Clausen, B. E., Burkhardt, C., Reith, W., Renkawitz, R., & Förster, I. (1999) · Transgenic Research · doi:10.1023/a:1008942828960 · Cited by 2,098
Schwenk, F., Baron, U., & Rajewsky, K. (1995) · Nucleic Acids Research · doi:10.1093/nar/23.24.5080 · Cited by 1,289
Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis
Brinkmann, V., Billich, A., Baumruker, T., Heining, P., Schmouder, R., Francis, G., Aradhye, S., & Burtin, P. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3248 · Cited by 1,273
Skeletal remodeling in health and disease
Zaidi, M. (2007) · Nature Medicine · doi:10.1038/nm1593 · Cited by 1,069
Mechanism of Action of Oral Fingolimod (FTY720) in Multiple Sclerosis
Chun, J., & Hartung, H.-P. (2010) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e3181cbf825 · Cited by 796
Self-citationBidirectional ephrinB2-EphB4 signaling controls bone homeostasis
Zhao, C., Irie, N., Takada, Y., Shimoda, K., Miyamoto, T., Nishiwaki, T., Suda, T., & Matsuo, K. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.05.012 · Cited by 777
Cited by
Kenkre, J., & Bassett, J. (2018) · Annals of Clinical Biochemistry: International Journal of Laboratory Medicine · doi:10.1177/0004563218759371 · Cited by 693
“By contrast, calcitonin-deficient mice show increased bone formation, and at physiological concentrations, calcitonin inhibits the actions of sphingosine-1phosphate, a coupling factor that links bone formation to resorption.(116,117)”
BackgroundUse of bone turnover markers in postmenopausal osteoporosis
Eastell, R., & Szulc, P. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30184-5 · Cited by 594
Physiological Bone Remodeling: Systemic Regulation and Growth Factor Involvement
Siddiqui, J. A., & Partridge, N. C. (2016) · Physiology · doi:10.1152/physiol.00061.2014 · Cited by 534
“bone formation by inhibiting the release of sphingosine 1-phosphate (S1P) from osteoclasts (82).”
BackgroundAmylin: Pharmacology, Physiology, and Clinical Potential
Hay, D. L., Chen, S., Lutz, T. A., Parkes, D. G., & Roth, J. D. (2015) · Pharmacological Reviews · doi:10.1124/pr.115.010629 · Cited by 400
“Subsequent studies have developed mice with 94%–100% deletion of the calcitonin receptor, using the Cre-LoxP system, targeting exons 13 and 14 or exons 6 and 7 (Davey et al., 2008; Keller et al., 2014).”
BackgroundMethodUpdate on the pharmacology of calcitonin/CGRP family of peptides: IUPHAR Review 25
Hay, D. L., Garelja, M. L., Poyner, D. R., & Walker, C. S. (2018) · British Journal of Pharmacology · doi:10.1111/bph.14075 · Cited by 370
“…is a hormone produced by C cells of the thyroid, whose role is to reduce plasma calcium and promote bone formation (Findlay and Sexton, 2004), although CT-deficient mice show a paradoxical inhibition of bone formation due to enhanced sphingosine-1-phosphate production (Keller et al., 2014).”
Background
Metadata
- Authors
- Keller, J., Catala-Lehnen, P., Huebner, A. K., Jeschke, A., Heckt, T., Lueth, A., Krause, M., Koehne, T., Albers, J., Schulze, J., Schilling, S., Haberland, M., Denninger, H., Neven, M., Hermans-Borgmeyer, I., Streichert, T., Breer, S., Barvencik, F., Levkau, B., Rathkolb, B., Wolf, E., Calzada-Wack, J., Neff, F., Gailus-Durner, V., Fuchs, H., de Angelis, M. H., Klutmann, S., Tsourdi, E., Hofbauer, L. C., Kleuser, B., Chun, J., Schinke, T., & Amling, M.
- Affiliations
- University Medical Center Hamburg-Eppendorf (DE)
- University of Potsdam (DE)
- Essen University Hospital (DE)
- Helmholtz Munich (DE)
- Ludwig-Maximilians-Universität München (DE)
- Scripps Research Institute (US)
- Corresponding author
- Amling, Michael
- ORCID
- Venue
- Nature Communications
- Published
- 2014-10-21
- Volume
- 5
- Issue
- 1
- Pages
- 5215-5215
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC4205484
- OpenAlex
- W1980751002
- Semantic Scholar
- e2f2d551f2624d9e90a89e2ee5d3017852508fd9
- Cited by
- 211
- References
- 64
- Citations by year
- 2026: 16 · 2025: 9 · 2024: 16 · 2023: 13 · 2022: 10 · 2021: 27 · 2020: 24 · 2019: 29 · 2018: 16 · 2017: 22 · 2016: 12 · 2015: 15 · 2014: 2
- FWCI
- 6.97
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Open access LMU (Ludwid Maxmilian's Universitat Munchen) (submittedVersion)
- publish.UP (University of Potsdam) (submittedVersion)
- mediaTUM (Technical University of Munich) (submittedVersion, other-oa)
- Site cant be reached (submittedVersion)
- OpenAgrar (submittedVersion)
- Funders
- INFRAFRONTIER (01KX1012)
- Deutsche Forschungsgemeinschaft (AM103/15-1, DA019674, 01KX1012)
- Bundesministerium für Bildung und Forschung (01GS0850, 01KX1012, 01GS0851)
- National Institutes of Health (5r01da019674-05, DA019674)
- National Institute on Drug Abuse (DA019674, R01-DA019674)
- National Institute on Deafness and Other Communication Disorders (DC009505, R21DC009505)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Sphingolipid Metabolism and Signaling
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Keywords
- calcitonin, calcitonin receptor, bone formation, osteoclasts, sphingosine-1-phosphate, S1P3 receptor, SPNS2, fingolimod, bone resorption, skeletal phenotype
- MeSH terms
- Alleles, Animals, Bone and Bones, Calcitonin, Crosses, Genetic, Female, Lysophospholipids, Mice, Inbred C57BL, Mice, Transgenic, Osteoblasts, Osteoclasts, Osteogenesis, Osteoporosis, Phenotype, Sphingosine, Signal Transduction, Porosity, Collagenases, Receptors, Calcitonin, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Calcitonin controls bone formation by inhibiting the release of sphingosine 1-phosphate from osteoclasts. https://app.cochat.ai/papers/10.1038/ncomms6215
- The paper
- Keller, J., Catala-Lehnen, P., Huebner, A. K., Jeschke, A., Heckt, T., Lueth, A., Krause, M., Koehne, T., Albers, J., Schulze, J., Schilling, S., Haberland, M., Denninger, H., Neven, M., Hermans-Borgmeyer, I., Streichert, T., Breer, S., Barvencik, F., Levkau, B., . . . Amling, M. (2014). Calcitonin controls bone formation by inhibiting the release of sphingosine 1-phosphate from osteoclasts. Nature Communications. https://doi.org/10.1038/ncomms6215
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.